Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis

Nathan, Steven D, Albera, Carlo, Bradford, Williamson Z, Costabel, Ulrich, Glaspole, Ian, Glassberg, Marilyn K, Kardatzke, David R, Daigl, Monica +7 more·2017·The Lancet Respiratory Medicine
DOI 10.1016/s2213-2600(16)30326-5

Cited by (337)

Items 201–300 of 337

  1. Comorbidities’ Effect on IPF: Pathogenesis and Management
    Andrea Salotti, Maria I. Chianese, Antonio Romallo, Anna De Nes, Darina Angoni, Alessandra Galantino, Maria Chernovsky, Lucrezia Mondini, Francesco Salton, Paola Confalonieri et al. · 2025 · Biomedicines
  2. Pirfenidone ameliorates liver steatosis by targeting the STAT3-SCD1 axis
    Shan Yang, Renzi Zhang, Wenzhen Deng, Shi-Chuan Chang, Yang Li, Sheng Li · 2023 · Inflammation Research
  3. Antifibrotics and mortality in idiopathic pulmonary fibrosis: external validity and avoidance of immortal time bias
    Hironao Hozumi, Koichi Miyashita, Eiji Nakatani, Yusuke Inoue, Hideki Yasui, Yuzo Suzuki, Masato Karayama, Kazuki Furuhashi, Noriyuki Enomoto, Tomoyuki Fujisawa et al. · 2024 · Respiratory Research
  4. Effect of antifibrotic agents on postoperative complications after lung transplantation for idiopathic pulmonary fibrosis
    Elsa Moncomble, Gaelle Weisenburger, C. Picard, Tristan Dégot, Martine Reynaud‐Gaubert, Ana Nieves, Jean‐François Mornex, Gaëlle Dauriat, Jonathan Messika, C. Godet et al. · 2023 · Respirology
  5. A robust data-driven genomic signature for idiopathic pulmonary fibrosis with applications for translational model selection
    Ron Ammar, Pitchumani Sivakumar, Gábor Járai, John Ryan Thompson · 2019 · PLoS ONE
  6. Pirfenidone affects human cardiac fibroblast proliferation and cell cycle activity in 2D cultures and engineered connective tissues
    Friederike Meyer, Gabriela Leão Santos, Thao Phuong Doan, Alisa Nicole DeGrave, Bastian Bues, Susanne Lutz · 2023 · Naunyn-Schmiedeberg s Archives of Pharmacology
  7. Undifferentiated Pleomorphic Sarcoma after Pirfenidone Use: A Case Report
    Christine A Moore, Aaysha Kapila · 2018 · The Permanente Journal
  8. Clinical, radiologic, and physiologic features of idiopathic pulmonary fibrosis (IPF) with and without emphysema
    Chenfei Li, Yan Wang, Qi Liu, Hai Zhang, Fei Xu, Zhenyun Gao, Xiaohui Wang, Guangyu Tao, Yuqing Chen, Wenwen Rong et al. · 2022 · Expert Review of Respiratory Medicine
  9. Pharmacological Treatment of Idiopathic Pulmonary Fibrosis (Update) and Progressive Pulmonary Fibroses: S2k Guideline of the German Respiratory Society
    Jürgen Behr, Francesco Bonella, Björn C. Frye, Andreas Günther, Lars Hagmeyer, Jörg Henes, Philipp Klemm, Dirk Koschel, Michael Kreuter, Gabriela Leuschner et al. · 2024 · Respiration
  10. Persistence of Antifibrotic Therapy in Patients with Idiopathic Pulmonary Fibrosis: A Pulmonary Fibrosis Foundation Patient Registry Study
    Tejaswini Kulkarni, Kevin R. Flaherty, Sachin Gupta, Yi-Hsuan Tu, Amy Hajari Case · 2024 · Annals of the American Thoracic Society
  11. Anti-fibrotic Treatment for Pulmonary Fibrosis Induced by COVID-19: A Case Presentation
    Bahar SAKIZCI UYAR, Kerem Ensarıoğlu, Bahar Kurt, Derya Özkan, Serra Özbal Güneş · 2021
  12. Biomarkers in Idiopathic Pulmonary Fibrosis
    Sanja Dj Stankovic, Mihailo Stjepanović, Milika Ašanin · 2021 · IntechOpen eBooks
  13. Overall drug treatment of idiopathic pulmonary fibrosis patients from national registries – a real-world study from Finland
    Jaana Kaunisto, Eija-Riitta M. Salomaa, Mari A. Koivisto, Marjukka Myllärniemi · 2023 · BMC Pulmonary Medicine
  14. Pirfenidone and mortality in idiopathic pulmonary fibrosis
    Paolo Spagnolo · 2016 · The Lancet Respiratory Medicine
  15. Are newly launched pharmacotherapies efficacious in treating idiopathic pulmonary fibrosis? Or is there still more work to be done?
    Riccardo Inchingolo, Carola Condoluci, Andrea Smargiassi, Annelisa Mastrobattista, Cristina Boccabella, Alessia Comes, Nicoletta Golfi, Luca Richeldi · 2017 · Expert Opinion on Pharmacotherapy
  16. Treating lung cancer in patients with interstitial lung disease: what do we know?
    Alexander Graur, Sydney B. Montesi, Michael D. Lanuti, Florian Johannes Fintelmann · 2023 · Journal of Thoracic Disease
  17. Enfermedades pulmonares intersticiales. Una perspectiva actual
    MAURICIO SALINAS F, MATÍAS FLORENZANO V, Verónica Wolff C., Juan Carlos Rodrı́guez, Hugo Valenzuela C., C. Fernández García, Álvaro Undurraga · 2019 · Revista médica de Chile
  18. New Twist to An Old Problem: COVID-19 and Idiopathic Pulmonary Fibrosis
    Pratap Upadhya, Ravindra Chari M, Gopal Chawla, Rohit Vadala, Madhusmita Mohanty Mohapatra · 2020 · Advances in respiratory medicine
  19. Deupirfenidone Compared with Pirfenidone and Placebo in Idiopathic Pulmonary Fibrosis (ELEVATE-IPF): a Phase 2b Randomized Placebo-Controlled Trial
    Maher, Toby M, Hamblin, Mark J, Choi, Won-Il, Case, Amy Hajari, Tomos, Ioannis P, Tzouvelekis, Argyrios E, Shore, Jessica E, Bergna, Miguel A, Golod, David, Elenko, Eric et al. · 2026 · American Journal of Respiratory and Critical Care Medicine
  20. Prognostic biomarkers for idiopathic pulmonary fibrosis: findings from ISABELA clinical trials
    Matthew J. Randall, Claus A. F. Andersen, Kevin M. Brown, Simon de Bernard, Paul Ford, Naftali Kaminski, Michael Kreuter, Sharlene Lim, Toby M. Maher, Niyati Prasad et al. · 2025 · ERJ Open Research
  21. Perspectives of people living with idiopathic pulmonary fibrosis: a qualitative and quantitative study
    Camilla S. Graham, Brianna Bisson, Jessica E. Shore, Emily Pardy, Frank Salisbury, LISA H. LANCASTER, Tejaswini Kulkarni · 2025 · BMC Pulmonary Medicine
  22. Overexpression of Decorin Optimizes the Treatment Efficacy of Umbilical Cord Mesenchymal Stem Cells in Bleomycin‐Induced Pulmonary Fibrosis in Rats
    Yaofeng Zhi, Minghui Shu, Pinsheng Tang, Yingjie Li, Min Guo, Jiongrui Deng, Haixin Mo, Meimei Wu, Baoyi Liu, Yan-Yang Mai et al. · 2025 · Stem Cells International
  23. Real-World Practice Patterns for Prevention and Management of Potential Adverse Events with Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
    Mark L. Wencel, Tmirah Haselkorn, Susan L. Limb, John L. Stauffer, Elizabeth A. Morgenthien, Karina Raimundo, Peter P. LaCamera · 2018 · Pulmonary Therapy
  24. Clinical management and acute exacerbations in patients with idiopathic pulmonary fibrosis in Spain: results from the OASIS study
    Esteban Cano-Jiménez, Ana Dolores Romero Ortíz, Ana Villar, María Jesús Rodríguez‐Nieto, Alba Ramón, Sílvia Armengol · 2022 · Respiratory Research
  25. Idiopathic Pulmonary Fibrosis: 8 Years On After Nintedanib and Pirfenidone Approval—What Is on the Horizon?
    Gioele Castelli, Elisabetta Cocconcelli, Nicol Bernardinello, Elisabetta Balestro, Paolo Spagnolo · 2023 · Current Pulmonology Reports
  26. Real-world patterns of pirfenidone use and safety in patients with idiopathic pulmonary fibrosis in Canada: Data from INSPIRATION PLUS
    Christopher J. Ryerson, Martin R.J. Kolb, Gerard Cox, Shane Shapera, Jeffrey J. Swigris, Charlene D. Fell, Marianne O’Brien, Cloris Xue, Jessica Rassi, Onofre Moran‐Mendoza · 2019 · Canadian Journal of Respiratory Critical Care and Sleep Medicine
  27. Advances in our understanding of distal progenitors in idiopathic pulmonary fibrosis: implications for novel therapeutics
    Hans‐Willem Snoeck · 2025 · European Respiratory Journal
  28. Progressive pulmonary fibrosis: a state-of-the-art review
    Vincent Cottin, Kevin K. Brown, Kevin R. Flaherty, Martin R.J. Kolb, David A. Lynch, Justin M. Oldham, Claudia Valenzuela, Marlies S Wijsenbeek, Athol Umfrey Wells · 2026 · European Respiratory Journal
  29. Advances in Heart Failure with Preserved Ejection Fraction Management - The Role of Sacubitril-Valsartan, Pirfenidone, Spironolactone and Empagliflozin: Is Success a Series of Small Victories?
    Γεώργιος Γιαννόπουλος, Maria S. Kousta, Ioannis Anagnostopoulos, Sofia Karageorgiou, Evangelia Myrovali, Gerasimos Deftereos, Nikolaos Fragakis, Gerasimos Siasos, Vassilios Pericles Vassilikos · 2023 · Current Pharmaceutical Design
  30. Historical eye on IPF: a cohort study redefining the mortality scenario
    Sara Tomassetti, Claudia Ravaglia, Sara Piciucchi, Jay Hoon Ryu, Athol Umfrey Wells, Luca Donati, Alessandra Dubini, Catherine Klersy, Valentina Luzzi, Leonardo Gori et al. · 2023 · Frontiers in Medicine
  31. Effects of exercise training on exercise capacity of patients with interstitial lung disease: a systematic review and meta-analysis
    Qian Zhao, Nan Mo, Rui Li, Tian Tian Wei, WenJin Xu, Jie Wang, Shanshan Li, Huifang Zhu, Guiling Miao · 2025 · BMC Pulmonary Medicine
  32. Natural products in the treatment of autoimmune hepatitis: A comprehensive review of therapeutic potential and mechanisms
    Jafar Salimian, Soheil Vazifedust, Majid Mirzaei Nodooshan, Hadi Esmaeili Gouvarchin Ghaleh · 2025 · International Immunopharmacology
  33. Comparison of Clinical Measures Among Interstitial Lung Disease (ILD) Patients with Usual Interstitial Pneumonia (UIP) Patterns on High-Resolution Computed Tomography
    Charlisa D. Gibson, Alok Bhatt, Himanshu Deshwal, Xiaochun Li, Judith D. Goldberg, Jane P. Ko, Rany Condos · 2020 · Lung
  34. Predictive factors for the long-term use of pirfenidone in patients with fibrosing interstitial lung disease
    Takuma Katano, Akimasa Sekine, Satoshi Ikeda, Hideaki Yamakawa, Toshihiro Misumi, Hiroko Okabayashi, Ryo Okuda, Hideya Kitamura, Tomohisa Baba, Shigeru Komatsu et al. · 2021 · Respiratory Investigation
  35. Searching for Novel Candidate Small Molecules for Ameliorating Idiopathic Pulmonary Fibrosis: a Narrative Review
    Kyung-il Kim, Rajib Hossain, Xin Li, Hyun Jae Lee, Hyun Jae Lee · 2023 · Biomolecules & Therapeutics
  36. Baseline Blood Levels of Mucin-1 Are Associated with Crucial On-Treatment Adverse Outcomes in Patients with Idiopathic Pulmonary Fibrosis Receiving Antifibrotic Pirfenidone
    Tang‐Hsiu Huang, Sheng‐Huan Wei, Hung-I Kuo, Hsin-Yu Hou, Chin‐Wei Kuo, Yau‐Lin Tseng, Sheng‐Hsiang Lin, Chao‐Liang Wu · 2024 · Biomedicines
  37. Enhanced production of Pirfenidone through a microfluidic system: A novel and thorough chemical kinetics investigation
    Farzad Bastan, Mohammad Kazemeini · 2024 · Chemical Engineering and Processing - Process Intensification
  38. Clinical Insights and Therapeutic Strategies for the Treatment of Interstitial Lung Disease in Patients with Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: Current Trends and Future Directions
    Justyna Fijołek, Anna Śniady · 2025 · Journal of Clinical Medicine
  39. Compound heterozygous mutation of RTEL1 in interstitial lung disease complicated with pneumothorax and emphysema: A case report and literature review
    Man Luo, Jiao‐Li Wang · 2022 · Respirology Case Reports
  40. Effects of Pirfenidone on Idiopathic Pulmonary Fibrosis Progression and Safety: Results of Multicenter Prospective Observational Study
    Sergey Nikolaevich Avdeev, M. M. Ilkovich, Stanislav A. Terpigorev, Sergey Valentinovich Moiseev, Igor E. Tyurin · 2023 · Life
  41. Idiopathic Pulmonary Fibrosis: What Is the Best Treatment?
    Fernando J. Martínez, Robert J. Kaner, Xiaoping Wu · 2017 · Barcelona Respiratory Network
  42. Pharmacologic Treatment of IPF
    Andrea Smargiassi, Giuliana Pasciuto, Emanuele Giovanni Conte, Mariarita Andreani, Roberta Marra, Luca Richeldi · 2018 · Respiratory medicine
  43. Diagnosis and treatment of interstitial lung disease: focusing on idiopathic pulmonary fibrosis
    Hye-Rin Kang, Sun Mi Choi · 2020 · Journal of Korean Medical Association
  44. POINT: Should Every Patient With Idiopathic Pulmonary Fibrosis Be Referred for Transplant Evaluation? Yes
    Steven D. Nathan · 2020 · CHEST Journal
  45. Fibrose pulmonaire idiopathique : actualisation des recommandations pratiques
    Vincent Cottin, Philippe Bonniaud, Jacques L. Cadranel, S. Jouneau, Sylvain Marchand-Adam, Hilario Nunès, Lidwine Wémeau-Stervinou, Bruno Crestani · 2022 · Revue des Maladies Respiratoires
  46. Idiopathic pulmonary fibrosis: a clinical case of long-term follow-up
    Galina L. Ignatova, Elena V. Blinova, Maria S. Belsner, M.A. Korotkaya · 2022 · Consilium Medicum
  47. Emerging Concepts in Therapeutic Interventions for Idiopathic Pulmonary Fibrosis
    Cody A. Schott, Michael P. Mohning, Joseph C. Cooley · 2025 · Seminars in Respiratory and Critical Care Medicine
  48. Nanomedicine-enabled ferroptosis intervention:from antitumor effects to immune remodeling in lung diseases
    Yunshuang Zhang, Weijie Huang, Kangyi Zhu, Qiaoyan Si, Tianyu Wang, Yan Qin · 2026 · Biomaterials
  49. Novel Approaches for the Treatment of Pulmonary Fibrosis with Emphasis on the Role of Galectin-3 Inhibitors as a Potential Therapeutic Approach
    Tanya Mathur, Indu Singh · 2023 · Current Drug Research Reviews
  50. Comparative Analysis of Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis: Epidemiology, Pathophysiology, Clinical Features, Diagnosis and Treatment
    Claudia Moreno Diaz, Estrella Caballeria, Jacobo Sellar閟 Torres · 2025 · Fibrosis
  51. Approved and Experimental Therapies for Idiopathic Pulmonary Fibrosis
    Giuliana Pasciuto, Riccardo Inchingolo, Carola Condoluci, Daniele Magnini, Bruno Iovene, Luca Richeldi · 2018 · Current Pulmonology Reports
  52. Co-trimoxazole to reduce mortality, transplant, or unplanned hospitalisation in people with moderate to very severe idiopathic pulmonary fibrosis: the EME-TIPAC RCT
    Andrew M. Wilson, Allan Clark, Anthony P. Cahn, Edwin R. Chilvers, William Duncan Fraser, Matthew Hammond, David M. Livermore, Toby M. Maher, Helen Parfrey, Ann Marie Swart et al. · 2021 · Efficacy and Mechanism Evaluation
  53. IDIOPATHIC PULMONARY FIBROSIS AND PROGRESSIVE PULMONARY FIBROSIS IN ADULTS: ADAPTED EVIDENCE-BASED CLINICAL GUIDELINE (DRAFT)
    Y. I. Feshchenko, V. K. Gavrysyuk, Н. Г. Горовенко, Oleksandr Dziublyk, T. O. Pertseva, M. M. Ostrovsky, A. V. Basanets, O. V. Bychenko, Y. O. Dziublyk, Lyudmyla Konopkina et al. · 2023 · Ukrainian Pulmonology Journal
  54. Fibrosis: The sixth element
    Alcibey Alvarado · 2018 · Clinical Research and Trials
  55. Raising awareness on physician-patient communication in IPF: an Italian multicenter study exploring the pulmonologist's perspective.
    Sara Tomassetti, Alfredo Sebastiani, Antonella Caminati, Tiberio Oggionni, Michele Davì, Alessandra Ghirardini, Monica M Martinoli · 2021 · Sarcoidosis vasculitis and diffuse lung diseases
  56. Pulmonary and Critical Care Medicine
    Derek A. Kruse, Kristina L. Bailey · 2021 · Springer eBooks
  57. Idiopathic pulmonary fibrosis: What has changed in the diagnosis and treatment from past to present?
    Ceyda Mahlec Anar, Oğuzhan Okutan, Aysun Şengül, Onur Yazıcı, Bülent Altınsoy · 2020 · Eurasian Journal of Pulmonology
  58. Cost-effectiveness of novel diagnostic tools for idiopathic pulmonary fibrosis in the United States
    Christopher J. Cadham, Joshua Jay Reicher, Michael C. Muelly, David W. Hutton · 2025 · BMC Health Services Research
  59. Bioinformatics-based identification of mirdametinib as a potential therapeutic target for idiopathic pulmonary fibrosis associated with endoplasmic reticulum stress
    Junwei Chen, Yuhan Du, Qi Yu, Dongyu Liu, Jinming Zhang, Tingyue Luo, Haohua Huang, Shaoxi Cai, Hangming Dong · 2025 · Naunyn-Schmiedeberg s Archives of Pharmacology
  60. The role of lung cancer in mortality rate in chronic fibrosing idiopathic interstitial pneumonia
    Beatriz Morales Chacón, Lydia Abásolo, José Luis Álvarez-Sala, María Asunción Nieto Barbero · 2025 · Scientific Reports
  61. Prognosis and prognostic factors for chronic fibrosing idiopathic interstitial pneumonias
    Hirotaka Nishikiori, Hirofumi Chiba · 2025 · Respiratory Investigation
  62. Effectiveness of antifibrotics on health-related quality of life in patients with interstitial lung disease: a systematic review and meta-analysis
    Ji Hye Lee, Shinhee Park, Hee‐Young Yoon · 2025 · Therapeutic Advances in Respiratory Disease
  63. Extracellular matrix and immune dysfunction: An overlooked relationship in idiopathic pulmonary fibrosis
    Upama Nyaupane, Kerri A. Johannson, Margaret Mary Kelly, FuiBoon Kai · 2025 · Experimental Lung Research
  64. Predictors of Disease Progression in Idiopathic Pulmonary Fibrosis Under Antifibrotic Therapy: A Retrospective Study
    Tomoo Kishaba, Mariko Higa, Hiroaki Nagano · 2025 · Cureus
  65. Efficacy and Safety of Pirfenidone for Mitigation of Interstitial Lung Abnormalities in COVID‐19 Patients: A Meta‐Analysis
    Ziyi Zhang, Xiang Fang, Jinhui Gao, Heming Sun, Ting Xu, Jiajia Wang · 2026 · Canadian Respiratory Journal
  66. A Scoping Review of Emerging Treatments in the Pipeline for Idiopathic Pulmonary Fibrosis: Future Perspectives
    Maria Eugenia Novara, Martina Chirulli, Patrizio Vitulo, Anna Carollo, Alessio Provenzani · 2026 · Biomedicines
  67. Should nintedanib be continued after acute exacerbation of idiopathic pulmonary fibrosis? A retrospective observational study using a nationwide database in Japan
    Hisayuki Shuto, Akihiko Hagiwara, Ryohei Kudoh, Hiroyuki Matsumoto, Shota Omori, Kiyohide Fushimi, Kosaku Komiya · 2026 · Respiratory Medicine and Research
  68. Endothelial-to-mesenchymal transition in atherosclerosis: mechanisms, therapeutic targets, and future perspectives
    Xinyi Cui, Yuanyuan Chen, Hailang Luo, Hongzheng Li, Zikai Yu, Hao Guo · 2026 · Frontiers in Cell and Developmental Biology
  69. Palliative Care of Respiratory Disease in Primary Care
    Patrick T. White · 2019 · Springer eBooks
  70. Microscopic Polyangiitis with Pulmonary Fibrosis: An Often-Recognized Manifestation of the Disease
    Liam Mahoney Clifford, Jamma Li, Christopher J. Renaud, Suran Loshana Fernando · 2019 · Case Reports in Rheumatology
  71. Modulatory effect of D-pinitol on bleomycin-induced pulmonary fibrosis in rats
    Yu-Ling Duan, Zhihua Wang, Yan-Xia Huo, Yang Zhang, Xiaoran Wu, Cuike Gong, Linlin Bai · 2023 · Asian Pacific Journal of Tropical Biomedicine
  72. Pulmonary Disease
    Stacey-Ann Whittaker Brown, Sidney S. Braman · 2023 · Springer eBooks
  73. Pulmonary Disease
    Stacey-Ann Whittaker Brown, Sidney S. Braman · 2024 · Springer eBooks
  74. DESAFIOS E PERSPECTIVAS NA GESTÃO DA FIBROSE PULMONAR IDIOPÁTICA: RUMO A TERAPIAS MAIS EFICAZES
    Aurélia Samila Silva, Vitória Vilas Boas da Silva Bomfim, Ingri Rochael Aguiar Xisto Brito, Rafael Bucciaroni, Paula Mendes Ribeiro e Oliveira, Breno Willams Wanderley Bezerra, Lídia Mirella Marques Costa, Het Jones Rios Neto · 2024 · Revista Ibero-Americana de Humanidades, Ciências e Educação
  75. Real-World Experience in the Clinical Use of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis in Taiwan: A Post-Marketing Surveillance Study
    Ping‐Hung Kuo, Chih‐Yen Tu, Chia‐Hung Chen, Kuo‐Chin Kao, Jeng‐Yuan Hsu, Meng‐Chih Lin, Inn‐Wen Chong, Chau‐Chyun Sheu · 2024 · Biomedicines
  76. Real-World Comprehensive Disease Management of Patients With Idiopathic Pulmonary Fibrosis
    Wendi R. Mason, Sally McLaughlin, Sophy Dedopoulos, Erin Mahoney, Tonja Meadows, John L. Stauffer, LISA H. LANCASTER · 2019 · Current Respiratory Medicine Reviews
  77. Nintedanib y pirfenidona en el tratamiento farmacológico de la fibrosis pulmonar idiopática: perspectivas actuales y futuras
    Javier Leonardo Galindo, Carlos Andrés Celis-Preciado, Pontificia Universidad Javeriana. Bogotá, Colombia, Mayra Edith Mejía, Unidad de Enfermedades Pulmonares Intersticiales. Instituto Nacional de Enfermedades Respiratorias, Ismael Cosío Villegas. Ciudad de México, México. · 2018 · Investigación Clínica
  78. Choice of Methodology Impacts Outcome in Indirect Comparisons of Drugs for Idiopathic Pulmonary Fibrosis
    David Alexander Scott, Emma Loveman, Jill L Colquitt, Katherine Ma O’Reilly · 2019 · Medicina
  79. Idiopathic interstitial pneumonias
    Alexander Averyanov, Е А Коган, Victor Lesnyak, I. E. Stepanyan, Данилевская Олеся Васильевна · 2019 · Elsevier eBooks
  80. Genetics of Idiopathic Pulmonary Fibrosis
    Susan K. Mathai, David A. Schwartz · 2020 · Respiratory medicine
  81. Severe COVID-19 Case with HRCT Score of 25/25: A Survival Story
    Param Shah, Satish N. Mahajan, Sunil Kumar, Sourya Acharya, Mona Vohra, Charan Singh Bagga, Dhruv Talwar · 2021 · Journal of Pharmaceutical Research International
  82. Idiopathic Pulmonary Fibrosis: What Is the Best Treatment?
    Xiaoping Wu, Robert J. Kaner, Fernando J. Martínez · 2017 · Barcelona Respiratory Network
  83. Idiopathic Pulmonary Fibrosis: What Is the Best Treatment?
    Xiaoping Wu, Robert J. Kaner, Fernando J. Martínez · 2017 · Barcelona Respiratory Network
  84. Pulmonary and Critical Care Medicine
    Derek A. Kruse, Kristina L. Bailey · 2016 · Springer eBooks
  85. Safety and efficiency of therapy with modern preparations of idiopathic pulmonary fibrosis
    E. A. Strel’tsov · 2018 · Medical Herald of the South of Russia
  86. Therapeutic Strategies for Interstitial Lung Diseases in Rheumatoid Arthritis
    Takafumi Suda · 2018 · Springer eBooks
  87. Sofortige Therapie nach Diagnose ist nötig
    Thomas Meißner · 2018 · Pneumo News
  88. Natural History of Idiopathic Pulmonary Fibrosis and Disease Monitoring
    Amen Sergew, Kevin K. Brown · 2018 · Elsevier eBooks
  89. Interstitial Lung Disease in Systemic Sclerosis: Lessons Learned from Idiopathic Pulmonary Fibrosis
    Augustine Chung, James English, Elizabeth R. Volkmann · 2019 · Current Treatment Options in Rheumatology
  90. IV. Advances in the Diagnosis and Treatment of Idiopathic Pulmonary Fibrosis
    Nobuhisa Ishikawa · 2018 · Nihon Naika Gakkai Zasshi
  91. Antifibrotische Therapie der idiopathischen pulmonalen Fibrose
    Philipp Markart, Fotios Drakopanagiotakis, Małgorzata Wygrecka · 2020 · Der Pneumologe
  92. Incidence and Disease Burden of Interstitial Lung Disease and Pulmonary Sarcoidosis from 1990 to 2019: Results from the Global Burden of Disease Study 2019
    Xiaoqian Ma, Lili Zhu, Huijuan Xiao, Huaping Dai, Chen Wang · 2020 · SSRN Electronic Journal
  93. Update in Diagnosis and Management of Interstitial Lung Diseases
    MAURICIO SALINAS F, MATÍAS FLORENZANO V · 2021 · Medical Research Archives
  94. An Introduction to Advanced Lung Disease
    Renea P. Jablonski, Mary E. Strek · 2021 · Respiratory medicine
  95. 持続可能な地域おこしにむけて : 「観光」と「スポーツ」をつなぐ (特集 からだ : スポーツ・教育・科学・文化・芸術からのアプローチ)
    哲也 大野 · 2013 · 桐蔭論叢
  96. WITHDRAWN: The Role of the Vascular Niche in Organ Fibrosis and COVID-19-Related Organ Damage and the Countermeasures adopted by Chinese and Western Medicine
    Hongyan Zhou, Nan Yang, Hua Xiu Sui, Xiangning Du, Qi Luo, Yang-Jianing Zhao, Yang-Wanxia Zhou, Qing Guan, Yue Zhou, Hong-Jie Qian et al. · 2022 · Pharmacological Research - Modern Chinese Medicine · Retracted
  97. 18. Molecular Mechanism and Drug Development of Idiopathic Pulmonary Fibrosis-Relationship between Specialty and Generality
    Arata Azuma · 2017 · Nihon Naika Gakkai Zasshi
  98. Comprehensive Care of Interstitial Lung Disease
    Marlies S Wijsenbeek, Catharina C. Moor · 2019 · Elsevier eBooks
  99. Palliative Care of Respiratory Disease in Primary Care
    Patrick T. White · 2018 · Springer eBooks
  100. Antifibrotic therapy and its indications for interstitial pulmonary fibrosis
    Martina Doubková · 2022 · Vnitřní lékařství